Literature DB >> 1936115

Terminal differentiation of human bone marrow cells capable of spontaneous and high-rate immunoglobulin secretion: role of bone marrow stromal cells and interleukin 6.

E Roldán1, J A Brieva.   

Abstract

Human bone marrow (BM) is a major site for in vivo immunoglobulin (Ig) formation. A subset of BM cells has been described which is capable of high-rate Ig secretion for 14 days in vitro without additional stimuli. Therefore, it provides a suitable model for analyzing the terminal B cell differentiation within the BM. The pleiotropic cytokine interleukin (IL)6 was found to be essential for the further maturation of BM spontaneous Ig-secreting cells, as can be deduced from the following findings: (a) the addition of anti-IL-6 antibodies inhibited most of their Ig production; (b) when endogenous IL6 synthesis in the culture was restricted by using serum-free medium, the missing IgG secretion could be restored by the addition of exogenous IL6; and (c) active IL6 synthesis by BM cells in fetal calf serum-containing cultures was confirmed by direct quantitation (range 0.37-2.1 ng/ml). The presence of IL6 during the first 3 days of culture was necessary for the induction of Ig secretion. Since neither the proliferation of these cells was elicited by IL6 nor the inhibition of the DNA synthesis in these cultures prevented the IL6-mediated Ig secretion, IL6 must act on the BM Ig-secreting cells as a differentiation factor. The source of the endogenous IL6 was, apparently, an adherent cell, since most of the IL6 production was present in this cell fraction. In contrast, the nonadherent BM cell fraction contained all of the mature Ig-secreting cells even though it produced little, if any, IL6; the combination of both populations completely restored Ig secretion. Finally, homogeneous populations of fibroblastic stromal cell derived from long-term BM cultures were totally efficient in inducing Ig secretion by purified BM CD38+ cells; this phenomenon was also demonstrated to be IL6 mediated. Taken together, these findings appear to indicate that BM Ig-secreting cells are not terminally differentiated, suggesting that their final maturation could be mediated by the BM microenvironment via the paracrine production of IL6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936115     DOI: 10.1002/eji.1830211105

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease.

Authors:  M Youd; C Blickarz; L Woodworth; T Touzjian; A Edling; J Tedstone; M Ruzek; R Tubo; J Kaplan; T Lodie
Journal:  Clin Exp Immunol       Date:  2010-04-29       Impact factor: 4.330

2.  In vitro production of TNF-alpha,IL-6 and sIL-2R in Chinese patients with ulcerative colitis.

Authors:  Bing Xia; Hai-Jian Guo; JBA Crusius; Chang-Sheng Deng; SGM Meuwissen; AS Pena
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

3.  Interferon-α induces unabated production of short-lived plasma cells in pre-autoimmune lupus-prone (NZB×NZW)F1 mice but not in BALB/c mice.

Authors:  Alexis Mathian; Mike Gallegos; Virginia Pascual; Jacques Banchereau; Sophie Koutouzov
Journal:  Eur J Immunol       Date:  2011-02-11       Impact factor: 5.532

4.  Gut microbial metabolites alter IgA immunity in type 1 diabetes.

Authors:  Juan Huang; James A Pearson; Jian Peng; Youjia Hu; Sha Sha; Yanpeng Xing; Gan Huang; Xia Li; Fang Hu; Zhiguo Xie; Yang Xiao; Shuoming Luo; Chen Chao; F Susan Wong; Zhiguang Zhou; Li Wen
Journal:  JCI Insight       Date:  2020-05-21

5.  Interleukin-6 protects anterior horn neurons from lethal virus-induced injury.

Authors:  Kevin D Pavelko; Charles L Howe; Kristen M Drescher; Jeff D Gamez; Aaron J Johnson; Tao Wei; Richard M Ransohoff; Moses Rodriguez
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

Review 6.  Effects of acute and chronic inflammation on B-cell development and differentiation.

Authors:  Derek Cain; Motonari Kondo; Huaiyong Chen; Garnett Kelsoe
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

7.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

8.  Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.

Authors:  H C Reinecker; M Steffen; T Witthoeft; I Pflueger; S Schreiber; R P MacDermott; A Raedler
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

9.  Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.

Authors:  Silvia Catellani; Ivana Pierri; Marco Gobbi; Alessandro Poggi; Maria Raffaella Zocchi
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

Review 10.  Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.

Authors:  Henrik E Mei; Stefanie Schmidt; Thomas Dörner
Journal:  Arthritis Res Ther       Date:  2012-11-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.